New plasminogen activators: A clinical review

被引：39

作者：

Ross, AM ^{[1
]}

机构：

[1] George Washington Univ, Cardiovasc Res Inst, Washington, DC 20037 USA

来源：

CLINICAL CARDIOLOGY | 1999年 / 22卷 / 03期

关键词：

thrombolysis; plasminogen activators; acute myocardial infarction; TNK-tissue plasminogen activator;

D O I：

10.1002/clc.4960220303

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rapid restoration of patency of the infarct-related artery is the key to preserving myocardium and improving survival. This understanding has led to the application of genetic engineering to develop new plasminogen activators with specific clinical features. These novel activators may provide faster and more complete reperfusion in a greater number of patients, and do so with less risk of bleeding and intracranial hemorrhage. This article reviews the pharmacologic profiles and clinical performance of several novel plasminogen activators engineered from the human tissue plasminogen activator molecule or developed from animal and bacterial proteins.

引用

页码：165 / 171

页数：7

共 41 条

[1] Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial [J].

Antman, EM ;

Giugliano, RP ;

McCabe, CH ;

Gibson, M ;

Adgey, AJJ ;

Ghali, M ;

Coussement, P ;

Anderson, KM ;

Scherer, J ;

Van de Werf, F ;

Braunwald, E .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :191A-191A

[2]

Bar FW, 1997, AM J CARDIOL, V79, P727

[3] Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (Recombinant plasminogen activator) and front-loaded, accelerated alteplase (Recombinant tissue plasminogen activator) in patients with acute myocardial infarction [J].

Bode, C ;

Smalling, RW ;

Berg, G ;

Burnett, C ;

Lorch, G ;

Kalbfleisch, JM ;

Chernoff, R ;

Christie, LG ;

Feldman, RL ;

Seals, AA ;

Weaver, WD .

CIRCULATION, 1996, 94 (05) :891-898

[4] New developments in thrombolytic therapy [J].

Bode, C ;

Peter, K ;

Nordt, T ;

Kohler, B ;

Moser, M ;

Ruef, J ;

Runge, MS .

FIBRINOLYSIS & PROTEOLYSIS, 1997, 11 :109-114

[5] CONJUGATION TO ANTIFIBRIN FAB' ENHANCES FIBRINOLYTIC POTENCY OF SINGLE-CHAIN UROKINASE PLASMINOGEN-ACTIVATOR [J].

BODE, C ;

RUNGE, MS ;

SCHONERMARK, S ;

EBERLE, T ;

NEWELL, JB ;

KUBLER, W ;

HABER, E .

CIRCULATION, 1990, 81 (06) :1974-1980

[6]

Cannon CP, 1997, CIRCULATION, V95, P351

[7]

CANNON CP, 1997, CIRCULATION S1, V96, P206

[8]

Collen D, 1997, CIRCULATION, V95, P463

[9] Recombinant staphylokinase variants with altered immunoreactivity .1. Thrombolytic properties and antibody induction [J].

Collen, D ;

Moreau, H ;

Stockx, L ;

Vanderschueren, S .

CIRCULATION, 1996, 94 (02) :207-216

[10] Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent [J].

Collen, D .

NATURE MEDICINE, 1998, 4 (03) :279-284

← 1 2 3 4 5 →